Pursuant to Regulation 30(2) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the schedule of Earnings Call to be held on November 10, 2023, at 8:30 AM (IST) on Unaudited Financial Results of the Company for the second quarter and half year ended September 30, 2023.
Thanking you,
Yours faithfully,
For AUROBINDO PHARMA LIMITED
ADIREDDY BADDIGA M
Digitally signed by ADIREDDY BADDIGAM Date: 2023.10.31 12:22:35 +05'30'
Please pre-register by clicking hereor copy and paste the following link in your browser
https://bit.ly/3tVVB9b
Earnings Presentation will be available on the Company's website link : Earnings Presentationpost results announcement
ADIREDDY BADDIGAM
Digitally signed by
ADIREDDY
BADDIGAM Date: 2023.10.31 12:23:11 +05'30'
Attachments
Original Link
Original Document
Permalink
Disclaimer
Aurobindo Pharma Ltd. published this content on 31 October 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 31 October 2023 08:41:43 UTC.
Aurobindo Pharma specializes in the research, development, manufacturing and marketing of active pharmaceutical ingredients and generic pharmaceuticals. The group's activity is organized around 2 product families :
- generic drugs: for the treatment of neurological, cardiovascular, viral, gastroenterological, ophthalmologic and chronic diseases;
- active pharmaceutical ingredients.
At the end of March 2018, the group operated 23 production sites in India (19), the United States (3) and Brazil.
Net sales are distributed geographically as follows: India (12%), the United States (46.5%), Europe (31.2%) and other (10.3%).
AUROBINDO PHARMA 
